BioCentury | Nov 20, 2020
Product Development

COVID vaccine updates for Pfizer-BioNTech, CureVac and Sinovac; plus Disbrow becomes permanent BARDA director

...Disbrow has accepted the role of permanent BARDA director. Disbrow has been acting director since Rick...
BioCentury | Nov 10, 2020
Politics, Policy & Law

Biden sticks with science, public health expertise for COVID-19 advisory board

...and her experience will likely help address racial and minority ethnic group disparities in COVID-19 outcomes. Whistleblower Rick...
BioCentury | Oct 9, 2020
Product Development

Supply constraints, logistic hurdles to limit mAb impacts on COVID-19

The speed of the development of COVID-19 mAbs highlights the strengths and weaknesses of the U.S. approach to pandemic countermeasures. On one hand, mAbs have been created and tested at record-breaking...
BioCentury | Oct 8, 2020
Product Development

Trump’s statements sure to increase demand for COVID-19 mAbs

Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs,...
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...By BioCentury Staff Former BARDA Director Bright leaving NIH Rick Bright, the former director of the...
...idebenone (Generic), Raxone (Other), Catena (Other) Vir Biotechnology Inc. GlaxoSmithKline plc BioNTech SE Pfizer Inc. Santhera Pharmaceuticals Holding AG Alexion Pharmaceuticals Inc. COVID-19 cov19sci cov19pol chs2020 rick...
BioCentury | Sep 4, 2020
Product Development

CEOs pledge rigorous Phase III testing for COVID-19 vaccines

As concerns grow around political pressure on FDA’s review process for COVID-19 countermeasures, a group of five biopharma CEOs reiterated Thursday that industry will not submit a COVID-19 vaccine or therapeutic for emergency use authorization...
BioCentury | Jul 17, 2020

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...EP4 receptor antagonists from Eisai Co. Ltd. (Tokyo:4523). The start-up, which is led by CEO Rick...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Jul 7, 2020
Politics, Policy & Law

FDA credibility on the line with White House pressure on hydroxychloroquine” The intrusion of politics into that decision was detailed in a whistleblower complaint by Rick...
BioCentury | Jun 19, 2020

Lyell, Pact combine T cell techs to take on solid tumors

...think need to be solved if we’re going to have successful therapy,” said Lyell CEO Rick...
...models. “Our growing confidence is that this combined approach may be the most generalizable answer.” Rick...
Items per page:
1 - 10 of 261